Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 11/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.73 |
| ▸ | CA12 | O43570 | 7/20 | 0.62 |
| ▸ | CA2 | P00918 | 7/20 | 0.62 |
| ▸ | CA9 | Q16790 | 7/20 | 0.62 |
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | SCD | O00767 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711759 | 0.85 | PTGS1 (0.64) | PTGS1PTGS2CA12CA2CA9 | |
| SCHEMBL5698536 | 0.85 | PTGS2 (1.00) | PTGS1PTGS2CA12CA2CA9 | |
| SCHEMBL14955951 | 0.84 | PTGS2 (0.52) | PTGS1PTGS2SCD | |
| SCHEMBL6728991 | 0.82 | PTGS2 (0.75) | PTGS1PTGS2CA12CA2CA9 | |
| SCHEMBL6721492 | 0.82 | PTGS2 (0.70) | PTGS1PTGS2CA12CA2CA9 | |
| SCHEMBL4575215 | 0.82 | CA2 (0.79) | PTGS1PTGS2CA12CA2CA9 | |
| SCHEMBL6808574 | 0.81 | PTGS2 (0.77) | PTGS1PTGS2CA12CA2CA9 | |
| SCHEMBL6725530 | 0.81 | PTGS2 (0.73) | PTGS1PTGS2CA12CA2CA9 | |
| SCHEMBL2891953 | 0.81 | TSHR (0.50) | PTGS1PTGS2SCD | |
| SCHEMBL9206986 | 0.81 | PTGS2 (0.73) | PTGS1PTGS2SCDDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101031564-A | Piperazine derivatives for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2007-09-05 | — | — | CN | claimed |
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
| CN-101031564-A | Piperazine derivatives for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2007-09-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | PTGS1 467/4885PTGS2 558/4885CA12 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.